Acadia Pharmaceuticals (ACAD) Change in Receivables (2013 - 2026)

Acadia Pharmaceuticals' Change in Receivables history runs 14 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 589.48% year-over-year to $13.9 million in Q1 2026; TTM through Mar 2026 was $34.6 million, a 1234.21% increase from a year earlier, with the FY2025 full-year figure at $22.7 million, up 1112.92% from the prior year.
• Change in Receivables advanced to $13.9 million in Q1 2026 per ACAD's latest filing, from $5.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $35.2 million in Q4 2023 and bottomed at -$18.8 million in Q3 2023.
• The 5-year median for Change in Receivables is $3.4 million (2023), against an average of $4.4 million.
• Biggest YoY gain for Change in Receivables was 7208.51% in 2023; the steepest drop was 351.99% in 2023.
• Year by year, Change in Receivables stood at $482000.0 in 2022, then soared by 7208.51% to $35.2 million in 2023, then sank by 117.59% to -$6.2 million in 2024, then surged by 190.46% to $5.6 million in 2025, then surged by 147.78% to $13.9 million in 2026.
• Per Business Quant, the three latest ACAD Change in Receivables figures stand at $13.9 million (Q1 2026), $5.6 million (Q4 2025), and $8.3 million (Q3 2025).